VEGFA and diabetes mellitus: There is a possibility that in case of patient with a poorly controlled or long-standing diabetes and previous history of ischemic attacks who have potential risk to cause systemic complication after anti-VEGF treatment, it would be more convenient to place agents with less systemic blockade of VEGF such as ranibizumab.